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Association of Osteoarthritis with Perfluorooctanoate and Perfluorooctane 
Sulfonate in NHANES 2003–2008
Sarah A. Uhl,1 Tamarra James-Todd,2 and Michelle L. Bell1
1School of Forestry and Environmental Studies, Yale University, New Haven, Connecticut, USA; 2Brigham and Women’s Hospital and 
Harvard Medical School, Boston, Massachusetts, USA
Ba c k g r o u n d: Perfluorooctanoate (PFOA) and perfluorooctane sulfonate (PFOS) are persistent, 
synthetic industrial chemicals. Perfluorinated compounds are linked to health impacts that may be 
relevant to osteoarthritis, cartilage repair, and inflammatory responses.
oBjectives: We investigated whether PFOA and PFOS exposures are associated with prevalence of 
osteoarthritis, and whether associations differ between men and women.
Me t h o d s : We used multiple logistic regression to estimate associations between serum PFOA and 
PFOS concentrations and self-reported diagnosis of osteoarthritis in persons 20–84 years of age 
who participated in NHANES during 2003–2008. We adjusted for potential confounders including 
age, income, and race/ethnicity. Effects by sex were estimated using stratified models and inter-
action terms.
re s u l t s: Those in the highest exposure quartile had higher odds of osteoarthritis compared with 
those in the lowest quartile [odds ratio (OR) for PFOA = 1.55; 95% CI: 0.99, 2.43; OR for 
PFOS = 1.77; 95% CI: 1.05, 2.96]. When stratifying by sex, we found positive associations for 
women, but not men. Women in the highest quartiles of PFOA and PFOS exposure had higher 
odds of osteo  arthritis compared with those in the lowest quartiles (OR for PFOA = 1.98; 95% CI: 
1.24, 3.19 and OR for PFOS = 1.73; 95% CI: 0.97, 3.10).
co n c l u s i o n s: Higher concentrations of serum PFOA were associated with osteoarthritis in 
women, but not men. PFOS was also associated with osteoarthritis in women only, though effect 
estimates for women were not significant. More research is needed to clarify potential differences in 
susceptibility between women and men with regard to possible effects of these and other endocrine-
disrupting chemicals.
key w o r d s : hazardous substances, osteoarthritis, perfluorooctane sulfonate, perfluoro  octanoate, 
public health. Environ Health Perspect 121:447–452 (2013).  http://dx.doi.org/10.1289/
ehp.1205673 [Online 14 February 2013]
Perfluoroalkyl acids (PFAAs) are a family of 
anthropogenic, fluorinated chains of 4–14 
carbon atoms (Lau et al. 2007). The unusual 
oil- and water-repelling characteristics of these 
molecules led to their use in > 200 industrial 
processes and consumer applications, including 
emulsifiers and surfactants; protective coatings 
for textiles, wood, leather, and metal products; 
nonstick cookware; grease-proof coatings for 
paper-based food storage containers; fire-retar-
dant foams; and, personal care products (Lau 
et al. 2007). Because of their wide range of uses 
and persistent chemical properties, PFAAs have 
become ubiquitous contaminants of humans 
and wildlife (Kuklenyik et al. 2005). Evidence 
of widespread human contamination with 
PFAAs was first published about 35 years ago 
(Guy et al. 1976). More recently, concentra-
tions of specific PFAAs in various environmen-
tal media, birds, fish, and humans, have been 
summarized by Lau et al. (2007). This review 
of the literature showed that PFAAs have been 
found in human serum worldwide, and can 
be measured in wildlife and in fresh and salt 
water even in remote areas (Lau et al. 2007). 
These chemicals bioaccumulate, and laboratory 
data suggest that PFAAs may act as endocrine-
  disrupting chemicals (Jensen and Leffers 2008). 
Despite the U.S. Environmental Protection 
Agency’s (EPA) safety reviews and agreements 
with some major manufacturers to voluntarily 
phase-out these chemicals in some locations, 
use of PFAAs continues, and exposure to many 
perfluorinated compounds, including PFOA 
(perfluorooctanoate, or perfluorooctanoic acid) 
and PFOS (perfluorooctane sulfonate), remains 
widespread (Calafat et al. 2007).
Osteoarthritis, the most common form 
of arthritis, affects approximately 27 million 
adults in the United States (Lawrence et al. 
2008) and disproportionately affects women, 
older individuals, and certain racial/ethnic 
groups. The disease is characterized by degen-
eration of tissues in the joints, which leads to 
chronic pain and joint stiffness. Individuals 
with osteoarthritis are more likely to report 
experiencing disability than those without the 
disease (Botha-Scheepers et al. 2006). The 
increasing prevalence of osteoarthritis in the 
United States is likely attributable, at least 
partly, to the aging population and concurrent 
increases in overweight and obesity (Bitton 
2009). Although the causes of osteo  arthritis 
are not fully understood, inflammation, 
abnormal calcium homeostasis, and oxidative 
stress are thought to be involved. In animal 
and in vitro models, PFOA and PFOS have 
been linked to inflammation (DeWitt et al. 
2009; Qazi et al. 2009; Singh et al. 2012), 
oxidative stress (Eriksen et al. 2010; Qian et al. 
2010), and disturbance of calcium   homeostasis 
(Kleszczyński and Składanowski 2011; Liu 
et al. 2011). In particular, PFOA is hypoth-
esized to increase inflammation through its 
ability to induce proinflammatory cytokines 
(Singh et al. 2012). Additionally, by binding 
to peroxisome proliferator-activated receptor 
(PPAR)–γ and PPAR-α, PFOA and PFOS 
could trigger changes in bone metabolism, 
which could relate to the onset and progres-
sion of osteoarthritis symptoms (Innes et al. 
2011). A previous study examined the relation-
ships between PFOA and PFOS exposure and 
osteoarthritis in participants living or working 
in Ohio and West Virginia communities with 
PFOA-contaminated drinking water (Innes 
et al. 2011). In these communities, they found 
a statistically significant 30% increased odds of 
self-reported physician-diagnosed osteoarthritis 
when comparing participants in the highest 
quartile of PFOA exposure with those in the 
lowest quartile, whereas they found a negative 
association for PFOS.
Because the previous study focused on 
individuals living in highly PFOA-exposed 
communities (Innes et al. 2011), we aimed 
to determine whether PFOA and PFOS 
exposures are associated with increased osteo-
arthritis prevalence in a population with more 
common exposure levels for PFOS. Our study 
participants are a representative sample of 
individuals from the U.S. population who par-
ticipated in the National Health and Nutrition 
Examination Survey (NHANES) from 2003 
through 2008. We hypothesized that levels of 
PFOA and PFOS exposure would be associ-
ated with the prevalence of osteo  arthritis and 
that associations would differ by sex because 
of hormonal differences.
Methods
NHANES is conducted by the National 
Center for Health Statistics [Centers for 
Disease Control and Prevention (CDC), 
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Atlanta, GA], which selects approximately 
5,000 representative study participants annu-
ally from the civilian, noninstitutionalized U.S. 
population. NHANES represents the most 
comprehensive attempt to understand human 
exposures to chemicals of concern (National 
Research Council 2006), and has been the sole 
data source for many cross-sectional studies 
of associations between chemical exposures 
and chronic disease. Participants are selected 
through a multistage probability sampling 
design. Each of the study participants under-
goes a physical examination by a health profes-
sional, which includes measurement of height 
and weight, and completes a series of surveys 
to ascertain demographic, health, and nutri-
tion information. Various biological samples 
are also collected for analysis from a random 
subset of study participants each year. Since 
1999, NHANES has operated as a continu-
ous annual survey with data released in 2-year 
cycles. Further details on study design are avail-
able from the CDC (2011a). NHANES was 
reviewed by the National Center for Health 
Statistics Ethics Review Board, and docu-
mented consent was obtained from partici-
pants. The variables used in our analysis are all 
publicly available through the CDC.
Exposure. NHANES has annually assessed 
perfluorinated compounds since 2003 among 
a subsample of participants. Perfluorinated 
compound exposures are estimated by 
measuring the concentrations of 18 perfluori-
nated chemicals in serum samples collected 
from a random sample of one-third of the 
study partici  pants ≥ 12 years of age (Kuklenyik 
et al. 2005). In summary, the CDC uses a 
solid-phase extraction method coupled to high-
performance liquid chromatography–tandem 
mass spectrometry. The limits of detection 
for PFOA and PFOS are 0.1 and 0.2 µg/g, 
respectively. At the time of our analyses, 
laboratory data were available through the 
2007–2008 NHANES cycle; we made use 
of information from 2003–2008 to increase 
the sample size. We restricted our analyses to 
persons 20–84 years of age, the group for which 
we had osteoarthritis status information and 
precise age information (in NHANES, the ages 
of all individuals ≥ 85 years of age are coded as 
85 years to ensure anonymity). For categorical 
models of exposure to PFOA or PFOS, we 
assigned participants to four exposure categories 
based on distributions in the study population 
as a whole. The cut points for PFOA were as 
follows: quartile 1 (≤ 2.95 ng/mL), quartile 2 
(> 2.95–4.22 ng/mL), quartile 3 (> 4.22–5.89 
ng/mL), and quartile 4 (> 5.89 ng/mL). The 
cut points for PFOS were as follows: quartile 1 
(≤ 8.56 ng/mL), quartile 2 (> 8.56–13.59   
ng/mL), quartile 3 (> 13.59–20.97 ng/mL), 
and quartile 4 (> 20.97 ng/mL).
Outcome. Information on the outcome of 
interest—osteoarthritis status—was collected 
by questionnaire via self-report. A previous 
study documented 81% agreement between 
a self-report of “definite” osteoarthritis and 
clinical confirmation (March et al. 1998), 
which suggests that osteoarthritis is likely to 
have been accurately reported in most cases. 
All NHANES participants ≥ 20 years of age 
were asked “Has a doctor or other health pro-
fessional ever told you that you had arthri-
tis?” Individuals who responded affirmatively 
were asked a follow-up question: “Which 
type of arthritis was it?” Possible answers 
to the latter question included rheumatoid 
arthritis, osteoarthritis, other type of arthri-
tis, unknown type, and decline to answer the 
question. Individuals who indicated that a 
doctor had provided a diagnosis of arthri-
tis, but who declined to answer the question 
about the type of arthritis or indicated that 
they did not know which type they had were 
classified as missing, and were excluded from 
the analyses. Those who indicated that they 
had rheumatoid arthritis or a form of arthritis 
other than rheumatoid or osteoarthritis were 
considered not to have osteoarthritis.
Covariates. Information on potential con-
founders was obtained from publicly available 
NHANES data. Potential confounders were 
selected based on prior reports of associations 
with PFOA and PFOS exposure levels (Calafat 
et al. 2007; Nelson et al. 2010) and osteo-
arthritis (Anderson and Felson 1988; CDC 
2011c). We assessed potential confounders as 
continuous variables unless otherwise noted, 
including age; sex (male vs. female); poverty 
status (a ratio of annual family income divided 
by the federal poverty threshold, calculated by 
the National Center for Health Statistics); self-
reported race/ethnicity (Mexican American, 
non-Hispanic white, non-Hispanic black, or 
other, including other Hispanic and multi-
racial); daily fat and caloric intake (based on 
responses during the first of two 24-hr dietary 
recall surveys); body mass index [BMI; weight 
(kilograms)/height (meters) squared]; self- 
reported history of bone fractures of the hip, 
wrist, or spine (yes/no); self-reported partici-
pation in moderate or vigorous sports, fitness, 
or recreational physical activities (yes/no); 
self-reported smoking status (current, former, 
never); and for women, self-reported parity 
(0, 1, or ≥ 2 children). Interpretation of results 
should consider that further research is needed 
to disentangle the relationships among some 
of these covariates, exposure, and health out-
come. For example, those with arthritis may 
engage in less physical activity.
Statistical analysis. We used multi  variable 
logistic regression to estimate associations 
between PFOA and PFOS and odds of osteo-
arthritis (yes/no). All analyses were conducted 
separately for PFOA and PFOS. First, we con-
firmed linear associations between exposure 
to PFOA or PFOS and odds of osteoarthritis 
using a test for linear trend. Then we devel-
oped models in which the exposures of interest, 
which were highly right-skewed, were treated 
as natural logarithm-transformed continuous 
variables. We developed separate models in 
which the exposures of interest were treated 
categorically. We first performed logistic 
regression with PFOA or PFOS and osteo-
arthritis without adjustment by any covariates 
to obtain crude estimates. We then adjusted 
for sociodemographic factors including age, 
poverty:income ratio, race/ethnicity, and sex. 
After eliminating highly correlated dietary and 
exercise variables, we performed backward 
model selection using likelihood ratio tests to 
build fully adjusted models including potential 
confounders that were statistically significant 
predictors of the outcome (p < 0.05).
We present results for the association 
between PFOA or PFOS and osteoarthritis 
based on three models: a crude (unadjusted) 
model; a model adjusted for sociodemographic 
factors (age, race/ethnicity, and poverty:income 
ratio); and a fully adjusted model with adjust-
ment for age, race/ethnicity, and poverty:income 
ratio, as well as variables selected to be associ-
ated with osteoarthritis based on the backward 
model selection.
We used multiplicative interaction terms 
and stratified models to assess potential effect 
modification by sex, age (29–49 years or 50–84 
years), and obesity status (BMI ≥ 30 or < 30). 
All models accounted for the complex, mul-
tistage sampling design of NHANES as rec-
ommended by the CDC (2011b). Stratum, 
cluster, and subsample weights were included 
in all logistic regression models using SAS sta-
tistical software survey procedures used in pre-
vious analyses of NHANES data (e.g., Meeker 
and Ferguson 2011; You et al. 2011). All 
analyses were performed using SAS statistical 
software version 9.2 (SAS Institute Inc., Cary, 
NC). Estimates were considered statistically 
significant based on two-tailed p-values < 0.05.
Results
Of 15,562 individuals 20–84 years of age who 
participated in NHANES during 2003–2008, 
PFOA and PFOS exposure information was 
available for 4,562 individuals, and 4,102 
of these individuals also had osteoarthritis 
status information. Participants with missing 
information for one or more model covariates 
(income, BMI, smoking, or history of bone 
fractures) were excluded. Approximately 6% 
(n = 243) of these 4,102 subjects had missing 
income information, and were excluded from 
our analyses. BMI information was missing 
for about 1.3% of the remaining subjects 
(n = 55). Smoking information was missing 
for < 1% of subjects (n = 2, both of whom 
had already been excluded due to other miss-
ing information). Information on history of 
bone fractures was missing for one individual Perfluorinated compounds and osteoarthritis
Environmental Health Perspectives  •  v o l u m e  121 | n u m b e r 4 | April 2013  449
who had been excluded due to missing 
income information.
Our study population included simi-
lar numbers of males and females, and had 
a relatively even age distribution (Table 1), 
and characteristics were similar to the over-
all NHANES sample of 15,562 individuals 
who participated during the study time period 
(data not shown). Compared with females, 
males had higher exposures to both PFOA 
(33.4% higher, p < 0.001) and PFOS (38.1% 
higher, p < 0.001). Mean serum PFOA and 
PFOS concentrations also increased with age 
(p < 0.001), except for a small decline in PFOA 
in the oldest age group (70–84 years) com-
pared with the next youngest group (Table 1). 
Exposures also differed by self-reported 
race/ethnicity for both PFOA and PFOS 
(p < 0.001), with the highest mean PFOA 
and PFOS concentrations in non-  Hispanic 
whites and non-Hispanic blacks, respectively, 
and the lowest mean concentrations of both 
exposures in Mexican Americans. PFOA and 
PFOS exposures increased with socioeconomic 
status as indicated by the poverty/income 
ratio (PFOA: p = 0.012; PFOS: p = 0.202). 
Exposure levels generally also increased with 
BMI for both exposures, though average con-
centrations were lower in obese participants 
than in overweight participants. Differences in 
exposure by smoking status were small, with 
levels for current smokers 9.0% higher and 
5.0% lower than for never-smokers for PFOA 
and PFOS, respectively.
Osteoarthritis cases were more likely to be 
female, older, non-Hispanic white, of higher 
income, and of higher BMI than controls. 
Exposure to PFOA and PFOS differed by 
osteoarthritis status, with cases having higher 
levels than noncases. The survey-weighted 
mean PFOA exposures for cases and noncases 
were 5.39 ng/mL (95% CI: 4.91, 5.87 ng/mL) 
and 4.87 ng/mL (95% CI: 4.59, 5.15 ng/mL), 
respectively. For PFOS, the survey-weighted 
mean exposures for cases and non-cases were 
24.57 ng/mL (95% CI: 21.49, 27.65 ng/mL) 
and 21.32 ng/mL (20.05, 22.59 ng/mL), 
respectively.
In logistic regression models of all partici-
pants (males and females), continuous natu-
ral logarithm-transformed PFOA and PFOS 
exposures were positively associated with 
osteoarthritis without adjustment (Tables 2 
and 3). However, associations were not sta-
tistically significant after full adjustment, and 
the OR for PFOS was attenuated toward 
the null. Comparing subjects in the highest 
quartile to the lowest quartile of serum PFOA 
and PFOS, we found statistically significant 
higher odds of osteoarthritis in the crude 
(unadjusted) models (Tables 2 and 3). The 
crude model for PFOA showed increased odds 
of osteoarthritis with higher exposure. Those 
in the fourth quartile of PFOA exposure had 
62% higher odds [odds ratio (OR) = 1.62; 
95% CI: 1.10, 2.39] of osteoarthritis than 
those in the first quartile. The unadjusted 
association for PFOS showed some evidence 
of a dose–response relationship. Study par-
ticipants in the third and fourth quartiles 
of PFOS exposure had 2.00 and 2.16 times 
higher odds of osteoarthritis than those in the 
first quartile (95% CI: 1.27, 3.17 and 1.37, 
3.39), respectively.
These results were generally robust to 
adjustment by covariates in the partially 
adjusted model (adjusting for age, sex, race/
ethnicity, and income) and the fully adjusted 
model (adjusting for covariates from the 
partially adjusted model as well as smoking, 
BMI, physical activity, and history of bone 
fractures), although some results lost statis-
tical significance. In our partially and fully 
adjusted models, those in the fourth quartiles 
of PFOA and PFOS exposure continued to 
have elevated odds of osteoarthritis compared 
to those in the first quartiles of exposure 
(Tables 2 and 3). After full adjustment, those 
in the highest quartile of PFOA exposure had 
a nonsignificant 1.55 times higher odds of 
osteoarthritis compared with those in the low-
est quartile (95% CI: 0.99, 2.43). After full 
adjustment, those in the highest quartile of 
PFOS exposure had a 1.77 times higher odds 
of osteoarthritis compared with those in the 
lowest quartile (95% CI: 1.05, 2.96).
In general, fully adjusted ORs were stron-
ger for obese participants compared with non-
obese participants [see Supplemental Material, 
Table S1 (http://dx.doi.org/10.1289/
ehp.1205673)] though differences were not 
statistically significant.
Table 1. Characteristics of study population.
Characteristic
n  
(% within group)
Osteoarthritis 
cases [n (%)]
PFOA, weighted 
mean (ng/mL)a
PFOS, weighted 
mean (ng/mL)a
Overall 4,102 (100) 365 (100) 4.83 21.23
Sex
Female 2,068 (50.4) 238 (65.2) 4.22 18.17
Male 2,034 (49.6) 127 (34.7) 5.63 25.10
Age (years)
20–29 825 (20.1) 4 (1.1) 4.69 17.46
30–39 728 (17.8 14 (3.8) 4.73 18.68
40–49 687 (16.8) 31 (8.5) 4.85 20.96
50–59 578 (14.1) 56 (15.3) 5.13 24.43
60–69 620 (15.1) 105 (28.8) 5.48 26.88
70–84 664 (16.2) 155 (42.5) 4.94 27.32
Race/ethnicity
Mexican American 816 (19.9) 30 (8.2) 3.71 15.11
Other Hispanic 246 (6.0) 11 (3.0) 4.81 17.95
Non-Hispanic white 2,017 (49.2) 271 (74.2) 5.16 22.12
Non-Hispanic black 861 (21.0) 42 (11.5) 4.53 24.73
Other 162 (4.0) 11 (3.0) 4.42 21.11
Poverty:income ratio
Below poverty line 712 (17.4) 40 (11.0) 4.04 17.19
100–200% poverty line 1,075 (26.2) 96 (26.3) 4.56 21.08
> 200% poverty line 2,072 (50.5) 205 (56.2) 5.20 22.69
Unknown 243 (5.9) 24 (6.6) 4.92 20.40
BMI
Underweight (≤ 18.5) 69 (1.7) 1 (0.3) 4.13 19.73
Normal weight (18.5–25) 1,163 (28.4) 70 (19.2) 4.72 20.06
Overweight (25–30) 1,458 (35.5) 125 (34.2) 5.19 22.80
Obese (≥ 30) 1,357 (33.1) 161 (44.1) 4.87 21.92
Unknown 55 (1.3) 8 (2.2) 3.31 19.03
Smoking status
Never 2,163 (52.7) 170 (46.6) 4.78 21.37
Former 1,041 (25.4) 149 (40.8) 4.93 23.35
Current 896 (21.8) 46 (12.6) 5.21 20.31
Unknown 2 (0.1) 0 (0.0) 5.77 25.62
History of bone fractures
Yes 467 (11.38) 73 (20.0) 5.31 23.01
No 3,634 (88.59) 292 (80.0) 4.86 21.61
Unknown 1 (0.02) 0 (0.0) 4.24 17.43
Vigorous physical activity
Yes 1,085 (26.45) 44 5.00 20.75
No 3,017 (73.55) 321 4.75 21.55
Moderate physical activity
Yes 2,155 (52.54) 175 (47.9) 4.98 22.00
No 1,946 (47.4) 190 (52.1) 4.83 21.12
Unknown 1 (0.02) 0 (0.0) 5.60 40.40
Overall ranges: PFOA 0.07–104.00, PFOS 0.14–435.00.
aArithmetic mean. Uhl et al.
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Stratified models by sex showed slightly 
stronger associations in women than in men 
(Figure 1). Fully adjusted ORs comparing 
the highest with the lowest quartile of PFOA 
exposure were 1.98 (95% CI: 1.24, 3.19) for 
women and 0.82 (95% CI: 0.40, 1.70) for 
men (Table 2). Corresponding ORs for PFOS 
were 1.73 (95% CI: 0.97, 3.10) for women 
and 1.56 (95% CI: 0.54, 4.53) for men 
(Table 3). These results were consistent with 
models with an interaction term for sex and 
exposure as a continuous variable, which also 
indicated stronger associations for females. In 
these interaction models, the odds of osteo-
arthritis were 1.51 times higher (p = 0.030) 
for women than men for PFOA, and 1.33 
times higher (p = 0.097) for PFOS in the fully 
adjusted model. Interaction models based on 
quartiles of exposure showed that the odds of 
osteoarthritis comparing the fourth and first 
quartiles of exposure were 1.93 times higher 
(p = 0.032) for women than men for PFOA, 
whereas for PFOS exposure, the odds for 
women were 1.27 times higher than for men, 
although not statistically different (p = 0.403).
Models stratified by age suggest stron-
ger associations among those 20–49 years of 
age compared with older participants (50–84 
years) for men and women combined, and 
among women [see Supplemental Material, 
Table S2 (http://dx.doi.org/10.1289/
ehp.1205673)]. The ORs comparing the 
highest to the lowest quartile of PFOA was 
4.95 (95% CI: 1.27, 19.4) in younger women, 
and 1.33 (95% CI: 0.82, 1.16) in older 
women, and corresponding ORs for PFOS 
were 4.99 (95% CI: 1.61, 15.4) in younger 
women, and 1.30 (95% CI: 0.65, 2.60) in 
older women. Results were not statistically 
different between older and younger women, 
or between men and women, and many strata 
had small sample sizes. Younger women in 
the highest quartile of PFOA exposure had 
4.95 times higher odds of osteoarthritis com-
pared to those in the lowest quartile of PFOA 
exposure, after full adjustment (95% CI: 1.27, 
19.4). For PFOS, younger women showed a 
similar increase in the odds of osteoarthritis 
when comparing those in the highest quartile 
of exposure with those in the lowest quartile 
(adjusted OR = 4.99; 95% CI: 1.61, 15.4).
Discussion
We found statistically significant associations 
between PFOA and PFOS and osteoarthritis. 
Positive associations between both chemicals 
and osteoarthritis were observed in females, 
but not males, both before and after adjust-
ment for potential confounders. Women 
with the highest levels of PFOA and PFOS 
appeared to have 1.98 and 1.73 times higher 
odds of osteoarthritis, respectively, compared 
with women in the lowest quartiles of expo-
sure to these chemicals. We estimated stronger 
associations for younger women (20–49 years) 
than older women (50–84 years) although 
these results should be interpreted with caution 
because of the small numbers of osteo  arthritis 
cases when stratified by sex and age. Innes 
et al. (2011) reported a stronger relationship 
between PFOA exposure and osteo  arthritis 
in younger men and women compared with 
older men and women, for whom a diagnosis 
would likely have taken place closer to the 
time of blood sampling. This result and our 
observation of the strongest associations in 
Table 2. Weighted associations between PFOA exposure and self-reported osteoarthritis in U.S. adults 20–84 years of age.
Exposure
Females and males (n = 3,809) Females (n = 1,921) Males (n = 1,888)
Crude OR  
(95% CI)
Adjusted OR 1a 
(95% CI)
Adjusted OR 2b 
(95% CI)
Crude OR  
(95% CI)
Adjusted OR 1a 
(95% CI)
Adjusted OR 2b 
(95% CI)
Crude OR  
(95% CI)
Adjusted OR 1a 
(95% CI)
Adjusted OR 2b 
(95% CI)
Quartile 1 Reference Reference Reference Reference Reference Reference Reference Reference Reference
Quartile 2 1.60 (1.03, 2.50)* 1.36 (0.84, 2.21) 1.32 (0.78, 2.23) 2.24 (1.43, 3.51)** 1.45 (0.84, 2.50) 1.44 (0.80, 2.62) 0.93 (0.45, 1.92) 1.07 (0.48, 2.36) 0.97 (0.42, 2.27)
Quartile 3 1.42 (0.93, 2.17) 1.18 (0.73, 1.90) 1.20 (0.72, 2.00) 1.93 (1.19, 3.14)** 1.16 (0.68, 1.96) 1.18 (0.67, 2.08) 1.01 (0.55, 1.85) 1.04 (0.50, 2.16) 0.98 (0.46, 2.08)
Quartile 4 1.62 (1.10, 2.39)* 1.45 (0.97, 2.17) 1.55 (0.99, 2.43) 3.71 (2.45, 5.62)** 1.87 (1.22, 2.87)** 1.98 (1.24, 3.19)** 0.70 (0.38, 1.31) 0.80 (0.40, 1.59) 0.82 (0.40, 1.70)
Continuousc 1.28 (1.05, 1.55)* 1.17 (0.96, 1.42) 1.20 (0.96, 1.49) 2.03 (1.58, 2.61)** 1.37 (1.03, 1.71)* 1.35 (1.02, 1.79)* 0.84 (0.65, 1.08) 0.89 (0.68, 1.18) 0.89 (0.67, 1.19)
Results for each sex were obtained from stratified models. 
aAdjusted for age (continuous), race/ethnicity (non-Hispanic white, non-Hispanic black, Mexican American, other race/multiethnic), socioeconomic status (poverty:income ratio, con-
tinuous). bAdjusted for variables above, and smoking (never, former, current), BMI (continuous), vigorous recreational activity (yes/no), prior hip, wrist, or spine fracture (yes/no). cORs 
represent the relative odds of osteoarthritis associated with a 1-unit increase in in-transformed PFOA. *p < 0.05. **p < 0.01. 
Table 3. Weighted associations between PFOS exposure and self-reported osteoarthritis in U.S. adults 20–84 years of age.
Exposure
Females and males (n = 3,809) Females (n = 1,921) Males (n = 1,888)
Crude OR  
(95% CI)
Adjusted OR 1a 
(95% CI)
Adjusted OR 2b 
(95% CI)
Crude OR  
(95% CI)
Adjusted OR 1a 
(95% CI)
Adjusted OR 2b 
(95% CI)
Crude OR  
(95% CI)
Adjusted OR 1a 
(95% CI)
Adjusted OR 2b 
(95% CI)
Quartile 1 Reference Reference Reference Reference Reference Reference Reference Reference Reference
Quartile 2 1.14 (0.67, 1.92) 1.02 (0.59, 1.75) 1.04 (0.58, 1.85) 1.11 (0.61, 2.03) 0.89 (0.48, 1.67) 0.88 (0.46, 1.70) 1.69 (0.57, 5.05) 1.43 (0.46, 4.39) 1.32 (0.41, 4.25)
Quartile 3 2.00 (1.27, 3.17)** 1.80 (1.08, 3.00)* 1.99 (1.14, 3.49)* 2.60 (1.46, 4.63)** 1.74 (0.92, 3.27) 1.92 (0.98, 3.75) 2.20 (0.77, 6.30) 1.90 (0.63, 5.76) 1.86 (0.55, 6.25)
Quartile 4 2.16 (1.37, 3.39)** 1.57 (0.97, 2.54) 1.77 (1.05, 2.96)* 3.31 (1.98, 5.54)** 1.54 (0.90, 2.66) 1.73 (0.97, 3.10) 2.52 (0.98, 6.50) 1.61 (0.62, 4.18) 1.56 (0.54, 4.53)
Continuousc 1.37 (1.12, 1.67)** 1.09 (0.90, 1.32) 1.15 (0.94, 1.40) 1.75 (1.37, 2.23)** 1.14 (0.90, 1.46) 1.22 (0.94, 1.58) 1.34 (0.97, 1.83) 0.95 (0.74, 1.23) 0.95 (0.73, 1.23)
Results for each sex were obtained from stratified models.
aAdjusted for age (continuous), race/ethnicity (non-Hispanic white, non-Hispanic black, Mexican American, other race/multiethnic), socioeconomic status (poverty:income ratio, con-
tinuous). bAdjusted for variables above, and smoking (never, former, current), BMI (continuous), vigorous recreational activity (yes/no), prior hip, wrist, or spine fracture (yes/no). cORs 
represent the relative odds of osteoarthritis associated with a 1-unit increase in in-transformed PFOA. *p < 0.05. **p < 0.01.
Figure 1. Associations between PFOA (A) and PFOS (B) exposure quartile (compared with the first quartile; 
reference) and odds of osteoarthritis, by sex. Points and vertical lines represent effect estimates and 95% 
CIs from fully adjusted, sex-stratified models, adjusting for age, race/ethnicity, poverty:income ratio, smok-
ing, BMI, vigorous recreational activity, and prior fracture (hip, wrist, or spine).
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younger women suggest the need for follow-up 
in future studies that could better assess expo-
sure before diagnosis and investigate differ-
ences in susceptibility to PFCs and other 
endocrine-disrupting compounds before and 
after menopause.
Differences in PFOA exposure levels and 
study population characteristics complicate 
the comparison of our results with those of 
Innes et al. (2011). The PFOA exposure refer-
ence categories used by Innes et al. encompass 
the exposures of most of our study participants 
and U.S. residents in general. Therefore, their 
results do not imply the absence of low-dose, 
potentially nonmonotonic effects of PFOA 
in the U.S. general population. In contrast to 
our findings, Innes et al. observed a negative 
association for PFOS at exposure levels that 
were quite consistent with those in our study. 
Although sample size limited our ability to test 
for effect modification by age and obesity sta-
tus, which was reported by Innes et al., we did 
not observe statistically significant differences 
according to age or obesity in our study popu-
lation; however, there was some suggestion of 
stronger associations in younger women than 
older women, and among obese compared 
with non-obese participants. Further research 
is needed to determine whether differences 
between study populations might be explained 
by differences in exposure, such that very 
high PFOA exposures might modify effects of 
PFOS, for example, or by differences related 
to race/ethnicity or other characteristics that 
might modify effects of exposure.
We focused on potential effect modifi  ca-
tion by sex because of previous animal litera-
ture suggesting that effects of PFOA and 
PFOS on osteoarthritis might be hormonally 
mediated, as well as evidence that the chemi-
cals might be excreted differently by males 
and females (Betts 2007). However, other 
studies did not identify differences in PFOA 
excretion according to sex (Bartell et al. 2010; 
Brede et al. 2010).
Although the previous study (Innes et al. 
2011) was able to focus on age and BMI differ-
ences in a population with very high levels of 
exposure to PFOA, the present study evaluated 
the associations between PFOA and PFOS and 
osteoarthritis among a representative sample of 
the U.S. population. Our findings suggest that 
females may be more susceptible than males to 
effects of perfluorinated compounds.
The biological mechanism(s) by which 
PFOA and PFOS may cause osteoarthritis are 
not known, but experimental findings suggest 
they have the potential to mimic and inter-
act with endogenous hormones, increase the 
expression of proinflammatory cytokines, and 
bind with PPARs, which are relevant to bio-
logical processes that might influence etiology 
and progression of osteoarthritis. In particular, 
PFOA and PFOS can bind to PPAR-α and 
PPAR-γ (DeWitt et al. 2009; Vanden Heuvel 
et al. 2006), which are involved with regula-
tion of glucose homeostasis, inflammation, 
and lipid metabolism and storage (Kersten 
et al. 2000). Very few studies have reported 
on sex differences between the associations 
of PFOA or PFOS and health outcomes in 
humans. However, a recently published pro-
spective cohort study from Denmark that 
examined the association between in utero 
PFOA exposure and risk of overweight at 
20 years of age found a statistically signifi-
cant association for females but not for males 
(Halldorsson et al. 2012).
Limitations of this research include the 
relatively small sample size, the cross-sectional 
study design, exposure assessment at a single 
time point for each participant, self-reported 
information on the outcome of interest and 
several covariates, missing data for some study 
participants, and the lack of information about 
the date of osteoarthritis onset. The use of exer-
cise as a potential confounder, while included 
in our fully adjusted model and incorporated 
in the analysis by Innes et al. (2011), war-
rants further investigation because arthritis 
may affect the ability to exercise. Additionally, 
potential effect modifiers should be examined, 
such as diabetes and many of the charac  teris-
tics investigated here (e.g., obesity), with a 
larger sample size. Due to the relatively long 
half-lives of PFOA and PFOS (Olsen et al. 
2007), the single serum samples likely pro-
vide reasonable estimates of long-term expo-
sure. Any exposure misclassification would 
be random and would be unlikely to differ 
based on disease status. Still, the single serum 
measurements could represent exposures fol-
lowing osteoarthritis onset, which could have 
occurred many years before the survey.
Another potential limitation of our work is 
that samples were taken at a single time point 
for each participant, and measured concentra-
tions in these samples may not reflect expo-
sures during etiologically relevant time periods. 
Evidence from NHANES suggests that PFOS 
levels decreased in the U.S. population dur-
ing the study period, whereas levels of PFOA 
have essentially remained stable (Kato et al. 
2011). Thus, if past exposures are more rele-
vant to osteoarthritis than recent exposures, 
associations based on current PFOS levels may 
underestimate potential effects.
Although the breadth of variables included 
in NHANES enabled us to examine and adjust 
for many potential confounders, residual con-
founding and possible overadjustment could 
be sources of bias. Our inclusion of BMI and 
prior history of bone fractures, which could be 
on a causal pathway between endocrine-system 
disruption and development of osteoarthritis, 
may have introduced bias toward the null.
As new information about the health 
consequences of PFAAs emerges, patterns of 
production and usage are changing. Global 
production of PFOS has dropped consider-
ably compared with 1999 levels following 
the primary manufacturer’s agreement to end 
production of the chemical, whereas global 
production of PFOA has increased during the 
same period (Lau et al. 2007). Recognizing the 
growing importance of PFOA, the U.S. EPA 
launched the PFOA Stewardship Program in 
2006: Working with the eight leading manu-
facturers of PFOA, the U.S. EPA developed 
a goal of eliminating usage and emissions of 
the chemical by 2015 (Lau et al. 2007). As 
these compounds are being used less, at least 
in some parts of the world, newer PFAAs are 
entering the global marketplace, dominated by 
molecules with shorter carbon chains that may 
be less persistent (Betts 2007). These substi-
tute compounds may present their own health 
and environmental hazards, and new evidence 
shows that certain substitutes can undergo 
chemical transformations in the environment 
yielding PFOS and PFOA (Betts 2007). Given 
the ongoing use of PFAAs and the global scale 
of human and environmental contamination, 
better understanding of the potential health 
effects of these chemicals, and of factors that 
might be used to identify susceptible subpopu-
lations, could help to inform public health 
policies aimed at reducing exposures or asso-
ciated health impacts. Future research could 
investigate the health impacts of newer PFAAs 
and the degree to which certain groups, such 
as women, may be particularly susceptible.
Conclusion
Although production and use of PFOA and 
PFOS have declined due to safety concerns, 
human and environmental exposure to 
these chemicals remains widespread. Better 
understanding of the health effects of these 
chemicals and identifying any susceptible 
subpopulations could help to inform public 
health policies aimed at reducing exposures 
or associated health impacts. In this cross-
sectional study of a representative sample of 
the adult U.S. population, PFOA and PFOS 
exposures were associated with higher preva-
lence of osteoarthritis, particularly in women. 
To our knowledge, the present analyses repre-
sent the first study of the association between 
perfluorinated compounds and osteoarthritis 
in a study population representative of the 
United Sstates. Future prospective studies are 
needed to establish temporality and elucidate 
possible biological mechanisms. Reasons for 
differences in these associations between men 
and women, if confirmed, also need further 
exploration. If replicated, these findings would 
support reducing exposures to PFOA and 
PFOS, and perhaps other PFAAs, to reduce 
the prevalence of osteoarthritis in women, a 
group that is disproportionately affected by 
this common chronic disease.Uhl et al.
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